N/A N=2 Treatment

Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease

Pyoderma Gangrenosum · Crohn's Disease · Ulcerative Colitis · Inflammatory Bowel Disease

Bottom Line

View on ClinicalTrials.gov: NCT00791557 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2013

Primary outcome: Primary: The Efficacy of Infliximab in Pyoderma Gangrenosum in Adult Subjects Who Have Inflammatory Bowel Disease — 1 participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Infliximab (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University Hospitals Cleveland Medical Center
Primary completion: Dec 2009

Outcome Measures

Outcome	Result	p-value
PRIMARY The Efficacy of Infliximab in Pyoderma Gangrenosum in Adult Subjects Who Have Inflammatory Bowel Disease	1	—

Summary

Subjects must be 18- 75 years old and have a history of both inflammatory bowels disease (Crohn's or ulcerative colitis) and pyoderma gangrenosum. This is a 6 month open label study of an intravenous (IV) medication. Visits occur every 2 weeks initially, then every 1-2 months later in the study.

Eligibility Criteria

Inclusion Criteria

Must Be ages 18-75
Must have both inflammatory bowel disease and moderate to severe pyoderma gangrenosum
Must never have received Infliximab for the treatment of pyoderma gangrenosum

Exclusion Criteria

Have had any previous treatment with monoclonal antibodies other than infliximab used to treat IBD or antibody fragments.
Have a history of serious infections

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00791557). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.